对 Pseudomonas aeruginosa 疫苗研发的图书统计分析,突出研究现状,演变和未来的机会
Shiqin Huang1, Yi Zhou2,3,4, Meiling Wu5
1Department of Pharmaceutics, Chongqing University Jiangjin Hospital, Chongqing University, Chongqing, People's Republic of China.
Naunyn-Schmiedeberg's archives of pharmacology
|January 7, 2026
概括
开发针对 Pseudomonas aeruginosa (P. aeruginosa) 的有效疫苗是具有挑战性的,因为它的多样性. 现在的研究重点是多个位的设计和先进的传递系统,以提供广泛的保护.
科学领域:
- 传染性疾病 传染性疾病
- 疫苗学 疫苗学 疫苗学
- 图书统计学 图书统计学
背景情况:
- 伪omonas aeruginosa (P. aeruginosa) 是医院获得感染的主要原因之一.
- 在P. aeruginosa的多药性耐药性是一个重要的全球健康问题.
- 疫苗开发受到抗原多样性和复杂的毒性因素的阻碍.
研究的目的:
- 为了绘制P. aeruginosa疫苗开发的研究格局.
- 确定关键趋势和新兴研究领域.
- 为未来的疫苗研究提供数据驱动的框架.
主要方法:
- 从科学网络和PubMed. 的1701篇出版物 (1970-2025) 的图书统计分析.
- 使用VOSviewer和CiteSpace进行数据分析.
- 包括关键字聚类和突发检测分析.
主要成果:
- 2013年以后,出版物的数量大幅增加,其中美国和中国是主要贡献者.
- 新兴的研究重点是多表位疫苗,生物大分子抗原 (OMP,多糖,囊泡) 和纳米粒子输送.
- 目前的趋势包括结构性疫苗学,逆免疫学和可生物降解的聚合物封装.
结论:
- 在P. aeruginosa疫苗开发方面的研究重点正在转变.
- 计算型疫苗设计与先进的输送系统相结合,有望提供广泛的保护.
- 这项研究提供了洞察力,以指导未来的P. aeruginosa疫苗研究工作.
相关概念视频
Microorganisms in Medicine and Therapeutics
928
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
928
Development of Antibiotic Resistance
1.3K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.3K
Vaccinations
51.2K
Overview
51.2K


